Continuous low volume delivery of intravenous treprostinil via a central venous catheter with a miniature pump in a conscious dog model

Journal of Vascular Access

Volumn 6, Issue 4, 2005, Pages 177-181

  Laliberte, Kevin ^a   Jerat, S ^b   Tenneson, K ^b   Wade, M ^a   Zaccardelli, D ^a  

^a UNITED THERAPEUTICS CORPORATION   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

407C pump; Catheter; Hickman ; Infusion; Patency; Remodulin ; Treprostinil sodium

Indexed keywords

UNIPROST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATHETER OCCLUSION; CENTRAL VENOUS CATHETERIZATION; CLINICAL PRACTICE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; FEASIBILITY STUDY; INFUSION PUMP; INFUSION RATE; MALE; NONHUMAN; PILOT STUDY; PULMONARY HYPERTENSION; REIMPLANTATION; VASCULAR PATENCY;

EID: 31644434495     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980500600404     Document Type: Article

References (9)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
2. Remodulin® (treprostinil sodium) Injection Package Insert. United Therapeutics Corporation, Research Triangle Park, North Carolina, USA. November 2004.
3. Phares K, Weiser WE, Miller SP, et al. Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents. Am J Health Syst Pharm 2003; 60: 916-922.
4. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin®) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44: 209-14.
5. Wade M, Baker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol 2004; 44: 503-509.
6. Jorgensen KA, Dyerberg J, Stoffersen E. A biphasic effect of prostacyclin (PGI2) on platelet aggregation. Thromb Res 1980; 19: 877-81.
7. Noguchi M, Fujii T, Minamide S. Comparative studies of measuring condition of activated partial thromboplastin time and contact factors in experimental animals. Jikken Dobutsu 1989; 38: 221-9.
8. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-7.
9. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.